Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gavi

- PMLiVE

CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers

First participant will be vaccinated on 22 December

- PMLiVE

Moderna receives FDA emergency authorisation for its COVID-19 vaccine

Moderna's vaccine is the second to receive FDA approval, following approval of Pfizer/BioNTech’s BNT162b2 vaccine

- PMLiVE

J&J completes enrolment for late-stage COVID-19 vaccine trial

Company announces that around 45,000 participants have been enrolled

- PMLiVE

Moderna scores FDA panel backing for mRNA-based COVID-19 vaccine

EMA also brings forward review meeting of vaccine

- PMLiVE

Valneva launches phase 1/2 COVID-19 vaccine trials in the UK

UK government has pre-ordered 60 million doses of candidate

- PMLiVE

FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine

Briefing document published ahead of advisory committee meeting

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021

85 million to 100 million doses will be available in the US

- PMLiVE

US secures 650,000 additional doses of Lilly’s COVID-19 antibody

This takes the total purchased amount to 950,000 doses

- PMLiVE

WHO set to review Pfizer/BioNTech COVID-19 vaccine for emergency use listing

Follows approval for emergency use in the UK yesterday

- PMLiVE

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links